Sanofi Pasteur completes acquisition of Acambis
This article was originally published in Scrip
Executive Summary
Sanofi Pasteurhas completed its acquisition of the UK-based vaccine developer Acambis for £285 million. The amount has increased from the £276 million that was proposed in Sanofi Pasteur's offer in July, primarily due to stock options. The acquisition will strengthen Sanofi Pasteur's R&D unit with projects such as the development of a Clostridium difficile vaccine, an influenza vaccine based on M2 protein and a pre-clinical programme to develop a vaccine against herpes.